Research Categories
- Anesthesia
- Arthroscopy
- Biologics/Biomaterials
- Cancer Devices
- Cardiovascular
- Cosmetic Devices
- Dental
- Diabetes
- Diagnostics
- Dialysis
- Drug Delivery
- Ear, Nose, Throat
- Endoscopy
- Gastrointestinal (GI)
- General Surgery
- Gynecology Devices
- Healthcare IT
- Hearing Devices
- Imaging
- Immunology
- Infusion Therapy
- Laparoscopy
- Minimally Invasive Surgery
- Neurology Devices
- Oncology
- Operating Room Equipment
- Ophthalmics Devices
- Orthopedics
- Patient Monitoring
- Peripheral Vascular
- Respiratory Devices
- Robotics & Navigation
- Sleep Apnea & Diagnostics
- Spine
- Stents
- Tissue Repair
- Urology
- Vascular Access
- Video Hi-Tech
- Women's Health
- Wound Care
Price Analysis by Dose & Setting
Showing all 8 results
Immunology Drugs Market Report Suite | United States | 2018-2024 | MedSuite (Includes 19 Reports)
The United States immunology drugs report provides market analysis, sizing, forecasts, dosage units sold, average selling prices, and market shares of the immunology drugs within 5 major diseases. The report analyses key factors instrumental in changing the market scenario and provides a forecast of the future immunology market in the United States. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.
more...
Immunology Drugs Market Report Suite | Europe | 2017-2023 | MedSuite (Includes 5 Reports)
The Europe immunology drugs report provides market analysis, sizing, forecasts, and market shares of the immunology drugs. The report analyses key factors instrumental in changing the market scenario and provide a forecast of the future immunology market across the major 5 countries in Europe. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.
more...Immunology Drugs Market Report Suite | Brazil | 2018-2024 | MedSuite (Includes 5 Reports)
The Japan and BRIC immunology drugs report provides market analysis, sizing, forecasts, and market shares of the immunology drugs. The report analyses key factors instrumental in changing the market scenario and provide a forecast of the future immunology market in Brazil, Russia, India and China. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.
more...Ankylosing Spondylitis Drug Market Analysis | Global | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis across the globe (12 countries), including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Ankylosing Spondylitis Drug Market Analysis | Brazil | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis outside the U.S. and Europe, including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Ankylosing Spondylitis Drug Market Analysis | United States | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis in the US, including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Ankylosing Spondylitis Drug Market Analysis | Europe | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis in Europe, including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...